{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:52:35Z","timestamp":1788580355217,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>With increased interest in lipoprotein(a) (Lp[a]) concentration as a target for risk reduction and growing clinical evidence of its impact on cardiovascular disease (CVD) risk, rigorous analytical performance specifications (APS) and accuracy targets for Lp(a) are required. We investigated the biological variation (BV) of Lp(a), and 2 other major biomarkers of CVD, apolipoprotein A-I (apoA-I) and apolipoprotein B-100 (apoB), in the European Biological Variation Study population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>Serum samples were drawn from 91 healthy individuals for 10 consecutive weeks at 6 European laboratories and analyzed in duplicate on a Roche Cobas 8000 c702. Outlier, homogeneity, and trend analysis were performed, followed by CV-ANOVA to determine BV estimates and their 95% CIs. These estimates were used to calculate APS and reference change values. For Lp(a), BV estimates were determined on normalized concentration quintiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Within-subject BV estimates were significantly different between sexes for Lp(a) and between women aged &amp;lt;50 and &amp;gt;50\u2009years for apoA-I and apoB. Lp(a) APS was constant across concentration quintiles and, overall, lower than APS based on currently published data, whereas results were similar for apoA-I and apoB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Using a fully Biological Variation Data Critical Appraisal Checklist (BIVAC)\u2013compliant protocol, our study data confirm BV estimates of Lp(a) listed in the European Federation of Clinical Chemistry and Laboratory Medicine database and reinforce concerns expressed in recent articles regarding the suitability of older APS recommendations for Lp(a) measurements. Given the heterogeneity of Lp(a), more BIVAC-compliant studies on large numbers of individuals of different ethnic groups would be desirable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaa054","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T12:12:21Z","timestamp":1581509541000},"page":"727-736","source":"Crossref","is-referenced-by-count":27,"title":["Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population"],"prefix":"10.1093","volume":"66","author":[{"given":"Noemie","family":"Clouet-Foraison","sequence":"first","affiliation":[{"name":"Northwest Lipid Metabolism and Diabetes Research Laboratories, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M","family":"Marcovina","sequence":"first","affiliation":[{"name":"Northwest Lipid Metabolism and Diabetes Research Laboratories, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guerra","sequence":"first","affiliation":[{"name":"Laboratory Medicine, Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasne K","family":"Aarsand","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway"},{"name":"Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Co\u015fkun","sequence":"first","affiliation":[{"name":"Acibadem Mehmet Ali Ayd\u0131nlar University, School of Medicine, Atasehir, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"D\u00edaz-Garz\u00f3n","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Quality Analytical Commission of Spanish Society of Laboratory Medicine (SEQCML), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Fernandez-Calle","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Quality Analytical Commission of Spanish Society of Laboratory Medicine (SEQCML), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Sandberg","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway"},{"name":"Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Ceriotti","sequence":"first","affiliation":[{"name":"Central Laboratory, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carobene","sequence":"first","affiliation":[{"name":"Laboratory Medicine, Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"2020043014260228100_hvaa054-B1","year":"2018"},{"key":"2020043014260228100_hvaa054-B2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"2020043014260228100_hvaa054-B3","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"key":"2020043014260228100_hvaa054-B4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoprotein and Vascular Diseases Division working group on best practices","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1373\/clinchem.2012.196733","article-title":"Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division working group on best practices","volume":"59","author":"Cole","year":"2013","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B6","doi-asserted-by":"crossref","first-page":"III-2","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"2020043014260228100_hvaa054-B7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2015.07.040","article-title":"Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter?","volume":"242","author":"Phillips","year":"2015","journal-title":"Atherosclerosis"},{"key":"2020043014260228100_hvaa054-B8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"2020043014260228100_hvaa054-B9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2020043014260228100_hvaa054-B10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020043014260228100_hvaa054-B11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"2020043014260228100_hvaa054-B12","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2020043014260228100_hvaa054-B13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020043014260228100_hvaa054-B14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"2020043014260228100_hvaa054-B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020043014260228100_hvaa054-B16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"2020043014260228100_hvaa054-B17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1515\/CCLM.1998.053","article-title":"Long-term variability of serum lipoprotein(a) concentrations in healthy fertile women","volume":"36","author":"Garnotel","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B18","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2020043014260228100_hvaa054-B19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/cclm-2015-0067","article-title":"Defining analytical performance specifications: consensus statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine","volume":"53","author":"Sandberg","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1258\/acb.2009.009006","article-title":"Reference change values: the way forward in monitoring","volume":"46","author":"Fraser","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"2020043014260228100_hvaa054-B22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/cclm-2014-1142","article-title":"Rationale for using data on biological variation","volume":"53","author":"Ric\u00f3s","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B23","first-page":"1","volume-title":"In: Biological variation from principles to Practice","author":"Fraser","year":"2001"},{"key":"2020043014260228100_hvaa054-B24","author":"Fraser"},{"key":"2020043014260228100_hvaa054-B25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10408363.2016.1150252","article-title":"Generation of data on within-subject biological variation in laboratory medicine: an update","volume":"53","author":"Braga","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2020043014260228100_hvaa054-B26","author":"Aarsand"},{"key":"2020043014260228100_hvaa054-B27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1373\/clinchem.2017.281808","article-title":"The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation","volume":"64","author":"Aarsand","year":"2018","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0009-9120(93)90119-Q","article-title":"Significance of various parameters derived from biological variability for lipid and lipoprotein analyses","volume":"26","author":"Pagani","year":"1993","journal-title":"Clin Biochem"},{"key":"2020043014260228100_hvaa054-B29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1515\/cclm-2016-0035","article-title":"Sample collections from healthy volunteers for biological variation estimates\u2019 update: a new project undertaken by the working group on biological variation established by the European Federation of Clinical Chemistry and Laboratory Medicine","volume":"54","author":"Carobene","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1373\/clinchem.2015.252296","article-title":"Biological variation: the effect of different distributions on estimated within-person variation and reference change values","volume":"62","author":"R\u00f8raas","year":"2016","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/cclm-2014-1127","article-title":"A checklist for critical appraisal of studies of biological variation","volume":"53","author":"Bartlett","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"2020043014260228100_hvaa054-B33","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1373\/clinchem.2012.187781","article-title":"Confidence intervals and power calculations for within-person biological variation: effect of analytical imprecision, number of replicates, number of samples, and number of individuals","volume":"58","author":"R\u00f8raas","year":"2012","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1373\/clinchem.2006.069369","article-title":"Reference change values for brain natriuretic peptides revisited","volume":"52","author":"Fokkema","year":"2006","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B35","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1373\/clinchem.2018.288415","article-title":"The EuBIVAS: within- and between-subject biological variation data for electrolytes, lipids, urea, uric acid, total protein, total bilirubin, direct bilirubin, and glucose","volume":"64","author":"Aarsand","year":"2018","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1515\/cclm-2011-0868","article-title":"Age dependence of within-subject biological variation of nine common clinical chemistry analytes","volume":"50","author":"Carobene","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/CCLM.1999.014","article-title":"Biological variation in lipoprotein(a)","volume":"37","author":"Nazir","year":"1999","journal-title":"Clin Chem Lab Med"},{"key":"2020043014260228100_hvaa054-B38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/clinchem\/40.4.574","article-title":"Biological variability of cholesterol, triglyceride, low-and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"2020043014260228100_hvaa054-B39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/5\/727\/33149834\/hvaa054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/5\/727\/33149834\/hvaa054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T18:44:29Z","timestamp":1588272269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/66\/5\/727\/5817934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,8]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaa054","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,4,8]]}}}